The IDEA (international duration evaluation of adjuvant chemotherapy) collaboration: Prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: Trial design and current status

Current Colorectal Cancer Reports

Volumn 9, Issue 3, 2013, Pages 261-269

  André, Thierry ^a   Iveson, Timothy ^b   Labianca, Roberto ^c   Meyerhardt, Jeffrey A ^d   Souglakos, Ioannis ^e   Yoshino, Takayuki ^f   Paul, James ^g   Sobrero, Alberto ^h   Taieb, Julien ⁱ   Shields, Anthony F ^j   Ohtsu, Atsushi ^g   Grothey, Axel ^k   Sargent, Daniel J ^k  

^a HÔPITAL SAINT ANTOINE   (France)

^b UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^c OSPEDALI RIUNITI   (Italy)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^f NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^g BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^j WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k MAYO CLINIC   (United States)

more..

Author keywords

5 Fluorouracil; Adjuvants pharmaceutic; Capecitabine; Chemotherapy; Colon cancer; Colonic neoplasms; Duration of therapy; Fluoropyrimidines; International collaboration; Leucovorin; Neuropathy; Oxaliplatin; Phase III; Stage III

Indexed keywords

CAPECITABINE PLUS OXALIPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLON CANCER; DATA ANALYSIS; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG MONITORING; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STATISTICS; STUDY DESIGN; TREATMENT DURATION;

EID: 84892371199     PISSN: 15563790     EISSN: 15563804     Source Type: Journal    
DOI: 10.1007/s11888-013-0181-6     Document Type: Article

References (18)

1. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-51.
2. ·· Andre T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109-16. The authors show that the FOLFOX4 regimen is a standard of care for stage III colon cancer.
3. Kuebler JP, Wieand HS, O'Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25:2198-204.
4. · Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29:3768-74. The authors show that oxaliplatin + 5FU bolus LV increase DFS at three years vs 5FU bolus LValone for stage III colon cancer.
5. ·· Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29:1465-71. The authors show that XELOX is another standard of care for stage III colon cancer.
6. Schmoll HJ, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA). In: Oncol JC, editor. 2012 Gastrointestinal Cancers Symposium 2012.
7. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352-8.
8. Haller DG, Catalano PJ, Macdonald JS, et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol. 2005;23:8671-8.
9. Andre T, Colin P, Louvet C, et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol. 2003;21:2896-903.
10. Andre T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007;25:3732-8.
11. Chau I, Norman AR, Cunningham D, et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol. 2005;16:549-57.
12. Abrams TA, Brightly R, Mao J, et al. Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer. J Clin Oncol. 2011;29:3255-62.
13. · Allegra CJ, Yothers G, O'Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011;29:11-6. The authors show that bevacizumab did not increase DFS at three years for stage III colon cancer. This study evaluated the modified FOLFOX6 regimen for stage III colon cancer.
14. Shulman LN, Cirrincione CT, Berry DA, et al. Six cycles of doxorubicin and cyclophosphamide or Paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J Clin Oncol. 2012;30:4071-6.
15. De Wit R, Roberts JT, Wilkinson PM, et al. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001;19:1629-40.
16. Alberts SR, Sargent DJ, Nair S. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307:1383-93.
17. De Gramont A, Van Cutsem E, Schmoll H-J, et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 2012;13:1225-33.
18. Taïeb J, Tabernero J, Mini E, et al. Adjuvant FOLFOX4 with or without cetuximab (CTX) in patients (pts) with resected stage III colon cancer (CC): DFS and OS results and subgroup analyses of the PETACC8 Intergroup Phase III trial. Annals of Oncol 2012;23; supplement 9, Late Braking Abstract 4; (IX 178).